Serum levels of substance P and response to antidepressant pharmacotherapy

Pharmacopsychiatry

Volumn 37, Issue 5, 2004, Pages 238-239

  Lieb, Klaus ^a   Walden, J ^a   Grunze, H ^b   Fiebich, B L ^a   Berger, M ^a   Normann, C ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; LAMOTRIGINE; PAROXETINE; PLACEBO; SUBSTANCE P;

ADJUVANT THERAPY; ANALYSIS OF VARIANCE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ENZYME IMMUNOASSAY; HUMAN; MOOD DISORDER; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RATING SCALE; SCORING SYSTEM;

ACUTE DISEASE; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; PAROXETINE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SUBSTANCE P; TRIAZINES;

EID: 4644313502     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-832599     Document Type: Article

References (6)

1. Bondy B, Baghai C, Minov C, Schüle C, Schwarz MJ, Zwanzger P, Rupprecht R, Möller HJ. Substance P serum levels are increased in major depression: preliminary results. Biol Psychiatr 2003; 53: 538-542
2. Herpfer I, Lieb K. Substance P and substance P receptor antagonists in the pathogenesis and treatment of affective disorders. World J Biol Psychiatr 2003; 4: 56-63
3. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E, Hale JJ, Mills SG, MacCoss M, Swain CJ, Harrison T, Hill RG, Hefti F, Scolnick EM, Cascieri MA, Chicchi GG, Sadowski S, Williams AR, Hewson L, Smith D, Rupniak NM. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281: 1640-1645
4. Lieb K, Ahlvers K, Dancker K, Strohbusch S, Reincke M, Feige B, Berger M, Riemann D, Voderholzer U. Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men. Neuropsychopharmacology 2002; 27: 1041-1049
5. Martensson B, Nyberg S, Toresson G, Brodin E, Bertilsson L. Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid. Acta Psychiatr Scand 1989; 79: 586-596
6. Normann C, Hummel B, Scharer LO, Horn M, Grunze H, Walden J. Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. J Clin Psychiatr 2002; 63: 337-344